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pN-E2 is a monoclonal antibody generated against recombi-
nant tumor necrosis factor-a (TNF-a) - treated human um-
bilical vein endothelial cells (Ee). PN-E2 recognized a mole-
cule with expression levels in lIitro that could .be 
downregulated by TNF, and in situ PN-E2 showed only 
weak reactivity with vascular Ee in normal skin, as assessed 
by immunohistoc?emical staining .. The ~xpression of~N-~2 
was considerably mcreased on Ee m vanous pathologIc skm 
lesions, including psoriasis, granulation tissue, and inflamed 
skin. PN-E2 antigen expression was analyzed in more detail 
in vitro on cultured Ee and fibroblasts by use of enzyme-
linked immunosorbent assay and fluorescence-activated cell 
sorter techniques. The expression level on human umbilical 
vein endothelial cells and capillary Ee was, in contrast to the 
in situ immunohistologic findings, invariably high. On fibro-
blasts, a low expression was found . Incubation of the Ee with 
recombinant TNF-a decreased expression by a factor of 2. 
Incubation ofEC with recombinant interferon-y resulted in a 
E ndothelial cells (EC) in tissue sections can be identified by the use of specific markers. Apart from EC-binding lectins, such as the Ulex Europaeus I lectin, specific monoclonal and polyclonal antibodies are applied in im-munohistochemical staining procedures [1]. A number 
of monoclonal antibodies more or less specific for EC have been 
developed, some of which detect well-known molecules (e.g., 
von Willebrand Factor, angiotensin-converting enzyme), whereas 
others react with unidentified molecules (e.g., PAL-E, EN-4, 14E5; 
[1,2]). Other monocl?nal antibodies have been g.enerated that react 
with leukocyte adheSIOn molecules that are speCIfically (E-selectm) 
or predominantly [vascular cell adhesion molecule (VCAM-l)] ex-
pressed by EC. A characteristic of the latter molecules is that they 
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Abbreviations: 
ATCC: American Type Culture Collection 
bFGF: basic fibroblast growth factor 
BSA: bovine serum albumin 
DAB: 3-di-amino-bezidine 
EC: endothelial cell(s) 
ELISA: enzyme-linked immunosorbent assay 
EMEM: Eagle 's modified essential medium 
FCS: fetal calf serum 
HFEC: human foreskin endothelial cells 
twofold increase in PN-E2 antigen expression, whereas other 
cytokines [recombinant interleukin (rIL)-la, rIL-1P, rIL-4, 
rIL-6], lipopolysaccharide, or recombinant basic fibroblast 
~rowth fac.tor had no effect. Immunoelectron microscopy of 
tIssue speC1~ens and EC preparations localized the antigen 
on the lummal membrane of the endothelium. Immunopre-
cipitatio.n followed by s~dium dodecyl sulfate - poly-
acrylamIde gel ele~trophoreS1S analysis revealed a major band 
a~ 90 kDa and a mmor band at 80 kDa under reducing condi-
tlons . ~nd bands of 180 ~nd 400 kDa under non-reducing 
condItions. Molecular weight and expression patterns itl vitro 
on Ee after incubation with cytokines excluded most of the 
known endothelium-specific molecules, with the possible 
exception of endoglin (the 44G4 antigen). We conclude 
from our findings that this new aI).tigen could be useful as a 
marker for endothelial activation in skin biopsy material. 
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are induced on EC by inflammatory mediators, such as inter/eukin 
(IL)-l and tumor necrosis factor (TNF)[3-9]. 
Inthis s~udy, we describe a ne:v monoclonal antibody (PN-E2) 
reactive With human EC, o~ whIch the corresponding antigen is 
expressed only we~kly on caplllary e~dothelium in healthy skin and 
only modera~e1y 111 oth~r normal ttssu.es. The expression of the 
antlge~1 on skm endotheh~,?, howe7'er, I.S considerably upregulated 
under mflammatory condmons and 111 sk111 lesions where Ee prolif-
eration occurs, such as cutaneous melanoma or granulation tissue. 
We describe its tissue distribution and demonstrate some character-
istics of the antigen ill vitro using cultured Ee. Unlike other mole-
cules upregulated under inflammatory conditions, the PN-E2 anti-
gen is present in high amounts on cultured EC. Of several tested 
HUVEC: human umbilical vein endothelial cells 
ICAM: intercellular adhesion molecule 
IFN: interferon 
Ig: immunoglobulin 
IL: interleukin 
LPS: lipopolysaccharide 
PAGE: polyacrylamide gel electrophoresis 
PBS: phosphate-buffered saline 
PLP: periodate/lysine/ paraformaldehyde 
PMA: phorbol myristate acetate 
SDS: sodium dodecyl sulfate 
TBS: Tris-buffered saline 
TNF: tumor necrosis factor 
VCAM: vascular cell adhesion molecule 
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inflammatory mediators, only TNF and interferon (IFN)-Y had an 
effect on the expression of the anti gen. 
MATERIALS AND METHODS 
Cells Cell lines were obtained from the American Type Culture 
Collection (ATCC) (Rockville, MD) and maintained in RPMI 
1640 DM (Flow Laboratories, Richmansworth, H ertfordshire, 
U.K.), complemented with 10% heat-inactivated fetal calf serum 
(FCS) (Gibco BRL, Paisley, Scotland, U.K.), 1 mM sodium pyru-
vate, 2 mM glutamine (Flow Laboratories), and 40 flg/ml genta-
mycin . Cell lines used were K562 (chronic myelogenous leukemia), 
U937 (histiocytic lymphoma), HL60 (promyelocytic leukemia), 
Daudi and RPMI 8226 (both B-celllymphoma), and CEM (T-cell 
lymphoma). 
Human umbilical vein endothelial cells (HUVEC) were isolated 
by coll agenase treatment essentially as described by Jaffe et at [10]. 
Cells were subcultured at 37"C and 5% CO2 in Eagle's modified 
essential med ium (EMEM) (Flow Laboratories), supplemented with 
15% heat-inactivated human serum, 15% FCS (Gibco BRL), 
150 flg/ml BC growth factor (isolated from calf brain, as described 
by Maciag et at [11 j), 2 mM glutamine,S U /ml heparin (Organon 
Teknika, Boxtel, The Netherlands), and antibiotics in fibronectin-
coated tissue culture fl asks (Costar, Cambridge, MA) . Cells were 
detached from culture fl asks using a solution of 0.125% trypsin 
(Difco, D etroit, MI) in 0.2% ethylenediaminetetraacetic acid/ 
phosphate-buffered sa line. 
Human foreskin endothelial cells (HFEC) were a kind gift from 
Dr. V. van Hinsbergh (Gaubius Laboratory, Leiden, The N ether-
lands) . They were propagated in EMEM supplemented with 10% 
heat-inactivated human serum, 10% newborn calf serum (Flow Lab-
oratories), 5 U /ml heparin , 10 ng/ml recombinant human basic 
fibroblast growth factor (bFGF), 2 mM glutamine, and antibiotics. 
Culture and cell detachment were identical, as described for 
HUVEC. 
Fibroblasts were isolated by collagenase digestion of foreskin 
fragments and propagated in Dulbec~o's modified e.ssent.ial medium 
(Flow Laboratories) supplemented Wlt~ 10% heat-~n~ct~vated FCS, 
1 mM sodium pyruvate, 2 mM glutamllle, and antibIOtics. Culture 
and cel l detachment were identical as described for HUVEC. 
Hybridoma Production Female BALB / c mice at 7 weeks of age 
were injected intraperitoneally with 5 X 106 TNF-O'-stimulated 
(1 nM for 72 h) HUVEC in 0.25 ml PBS on the left side of the body 
and the same amount of cells in 0.25 ml CFA on the right side of the 
body. After 2 months, the mice received on 4 subsequent days an 
intrave nous booster of 3 X 106 TNF-stimulated HUVEC in 0.3 ml 
PBS. On the fifth day, splenocytes were obtained by removing and 
mincing the spleen of an immunized animal. Hybridomas were 
generated by fusing splenocytes with the SP2/0 fu sion pa~tner. An 
enzyme-linked immunosorbent assay (ELISA) on unstimulated 
versus TNF-treated HUVEC was used to screen hybridoma culture 
supernatants. Hybridomas showing a differential reaction pattern 
were further analyzed. 
Cytokines All cytokines and growth factors u~ed in this study 
were from human origin and produced by recomblllant DNA tech-
niques . T NF-O', IL-4, and I~N-y were generous gifts from 
Boehringer Ingelheim (IngelllClm, Germany); IL-10', IL-1,8, and 
IL-6 were purchased from Genzyme (Sanbio , Uden, the N ether-
lands); and bFGF was a kind gi ft from Dr. R. Peek (Department of 
Molecular Biology, Faculty of Science, University of Nijmegen) . 
The effect of the cytokines or growth factors on PN-E2 expression 
was assessed after 4, 8, 24, and 72 h of incubation. Cytokines and 
growth facto rs were tested over the following concentration ranges: 
TNF-O', 0. 1- 100 nM; IL-10', IL-1,8, IL-4, and IL-6, 1 - 1000 U / 
ml; lipopolysaccharide (LPS) , 1- 50 flg/ml; bFGF, 1 - 100 ng/ml. 
Monoclonal Antibodies Anti-HLA class I monoclonal antibody 
W6/32 was obtained from the ATCC (Rockville, MD). Anti-
HLA-DR was purchased from Becton-Dickinson (Mountain View, 
CAl. Anti - intercellular adh esion molecule (ICAM)-l antibody 
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CL203 [12] was a generous gift from Dr. S. Ferrone (Department of 
Immunology and Microbiology, N ew York Medical College, Val-
halla, NY) . 
ELISA HUVEC or fibrobl as ts were seeded in gelatin-coated, 96-
well microtiter plates (Costar) at 2 X 104 cells/well and allowed to 
grow to confluence in the appropriate medium for 3 days. In some 
experiments, cells were incubated with cytokines durin g the 
growth period in the microtiter plate. Cells were fixed with 0.025% 
glutaraldehyde in PBS for 10 min at room temperature, and weJls 
were blocked with 1 % gelatin in PBS for 30 min at 37 °C to prevent 
non-specific binding of antibody. After washing with PBS, the 
wells were successively incubated for 30 min at 3rC with monO-
clonal antibody and with polyclonal peroxidase-labeled goat -anti-
mouse immunoglobulin (Ig), heavy and light chain (Nordic, 
Tilburg, The Netherlands), both di luted in PBS/1 % gelatin. Sub-
strate for the enzyme was then added [8 mg/ml 5-aminosalicylic 
acid (Sigma, St. Louis, MO) in 50 rnM phosphate buffer with 
0.025% H 20 2]· Color development was measured after 30 min by 
reading the optical density at 450 nm in a Titertek ELISA plate 
reader (Flow Laboratories). The degree of specific monoclonal anti-
body binding was calculated by subtracting background values of 
negative controls from all test values. 
Indirect Immunofluorescence HUVEC, fibroblasts, or 
HFEC , either untreated or treated with cytokines, were detached 
from culture flasks by trypsin treatment, washed, and incubated 
with monoclonal antibodies in suspension at 105 cells per incuba-
tion at 4 °C. After removing unbound antibody by washing with 
PBS/ 1 % bovine serum albumin (BSA)/O.l % N aN 3 , cells were 
sta ined with fluorescein isothiocyanate - conjugated sheep - anti-
mouse F(ab'lz fragments (Cappel, Organon Teknika, Boxtel, The 
N etherlands). Ce lls were subsequently fixed in 1 % paraformalde-
hyde, and suspensions were analyzed using a flow cytometer 
(Coulter). 
Immunohistochemical Staining Air-dried tissue sections 
(4 flm) were fi xed in acetone for 10 min and subsequently incubated 
with monoclonal antibody (usually culture supernatant diluted 
1 : 10 in PBS/l % BSA) for 60 min at room temperature. After a 
5-min wash in PBS, the sections were incubated for 30 min with 
polyclonal peroxidase-conjugated rabbit anti-mouse IgG heavy-
and light-chain antibody (Dakopatts, Glostrup, Denmark) diluted 
1 : 160 in PBS/1 % BSA. After another 5-min wash in PBS, sections 
were incubated with 0.075% 3-di-amino-benzidine (DAB) (Sigma) 
in PBS with 0.01 % H 20 Z for 5 min , washed, counterstained with 
hematoxylin, and mounted. 
Immunoelectron Microscopy Punch biopsies from involved 
and uninvolved skin from patients with psorias is were fi xed for 3 h 
in periodat~/ l ysine/paraforn:aldehyde (PLP) , washed with Tris-
buffered sal1l1e (TBS), and nnsed III 2.3 M sucrose for 30 min at 
room temperature. Samples were snap-frozen in liquid nitrogen, 
and 20-fll11 sections were cut on a cryostat. Sections were incubated 
with mo.noclonal ~ntibody for 18 h at 4 ~ C and, after washing with 
TBS, With perOXidase-conJugated rabbit anti-mouse IgG (Dako-
parts) for 1 h at room temperature. Sections were developed in a 
s?lution of 0~075% Df.-B ~nd 0.01 % H20 2 in TBS. After post-fixa-
tion With 1 Vo OS04 In I alade buffer for 10 min, sections were 
dehydrated and embedded in Epon 812 (Merck, Darmstadt, Ger-
many) . Ultrathin sections were cut, counterstained with uranyl ace-
tate, and examined and micrographed on a Jeol 1200EX electron 
microscope at 40 kV. 
Cultured HUVEC were stained with PN-E2 and subsequently 
labe led with immunogold. Cells were removed from the culture 
flask with trypsin, wasbed~ and resuspended in the fi xing agent 
(PLP). After a fixatIOn penod of 30 min, cell s were washed and 
resuspended in 10% gelatin in PBS at 3rc. After lowering the 
temperature, the congealed cubes of gelatin containing the cells 
w.ere Incubated 111 2.3 M s.ucrose for 45 min and frozen in liquid 
I1Itrogen, and ultracryosectlons were cut. These sections were incu-
bated with PN-E2 and labeled with goat anti-mouse IgG conju-
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gated w ith lO-nm gold particles (Amersham, Buckinghamshire, 
UK). Sections were examined and photomicrographed on a Jeol 
1200EX electron microscope at 40 kv. 
InuJlunoprecipitation and Sodium Dodecyl Sulfate Polyac-
rylamide Gel Electrophoresis (SOS-PAGE) EC were meta-
bolically labeled for 4 h with 150 J1.Ci [35S]methionine (Amersham, 
Houten, The Netherl ands) in 5 ml methionine-free EMEM, supple-
mented with 15% dialyzed FCS, gentamycin, and glutamine, after 
first incubating the cells for 4 h in the same medium without 
(3sSJmethionine. After three washes with PBS, cells were removed 
from the tissue culture flask non-enzymatically (see above), and 
treated w ith lysis buffer (0.1% SDS/l% nonidet-40/0.5% Na-
deoxycholate/PBS). After centrifugation to remove nuclear debris , 
radiolabeled EC lysates were immunoprecipitated essentially as de-
scribed by Tamura et af [13]. Briefly, Costar 96-wells enzyme itr1-
m unoassay plates were coated with 100 J1.l of a 100-llg/ml solution 
of affinity-purified goat-anti-mouse antibody (Cappel) for 18 h at 
4 ° C. After washing with PBS/O.05% Tween-20, specific monoclo-
nal antibody (either culturc supernatant or ascites, 1: 100) was 
added to the wells and incubatcd for 4 h at 4°C, followed by another 
washing step. Wells werc then incubated with 200 Ill/well 
PBS/1 % BSA/1 % normal mouse serum for 2 h at room tempera-
ture, and, after washing, radiolabeled cell lysate was added at 
2 X 106 cpm/well. After incubation of the plate for 18 h at 4°C, 
wel ls were washed extensively with lysis buffer. Bound antigen was 
extracted from the wells by incubation with sample buffer for 
15 min at 60 °C and analyzed by SDS-PAGE. Gels were dried and 
autoradiographed. 
RESULTS 
Monoclonal Antibody PN-E2 Detects an Endothelial Cell-
Associated Antigen Oownregulated by TNF Monoclonal an-
tibodies wcrc generated against TNF-a-treated HUVEC. Hybri-
doma supernatants were screened using an ELISA to detect clones 
producing antibodies reacting differentially with TNF-a - treated 
HUVEC 
HFEC 
HFF 
... CELL NUMBER 
PN-E2 ICAM-\ HLA cl. n 
~ LOG FLUORESCENCE INTENSITY 
. 
" /\ 
!,j\ 
Figure 1. Effect of cytokine treatment on expression of membrane mole-
cu les on human EC and fibroblasts . C ultured venous EC (HDVEC), capillary 
EC (HFEC), and fibroblasts (HFF) were either not treated (solid curves) or 
were treated for 3 d with 10 11M T NF (dos/red CII rves) or 200 D/ml IFN-)I 
(doltCd curves). Surface expression of PN-E2, ICAM-1, and HLA-OR was 
assessed using /low cytometric analys is. 
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versus untreated HUVEC. This resulted in the isolation of several 
monoclonal antibodies showing an increased reaction with TNF-
a- treated HUVEC compared with untreated cells. Three of these 
monoclonal anti?odies (PN-E4, PN-E8, and PN-E12) were fOUJld 
to b~ reactive wlt~ ICAM-l, as determined by tissue distribution 
stud ies, reaction With COS (monkey kidney) cells transiently trans-
fectc? With ICA!"1-1 eDNA, expression patterns on HUVEC in 
reaction to cytokme treatment , and immulloprecipitatioll of a 100-
kDa protein (data not shown). 
One monoclonal antibody (PN-E2) was selected because it 
reacted strongly with untreated HUVEC and to a much lesser ex-
tent with TNF~stimulated cells. Figure 1 (lift) shows binding of 
m.onoclonal antibody PN-E2 to resting (solid CIIrve) and TNF-O'-
stImulated (dotted w~ve) HUVEC. Because addition of cytokines or 
growth factors may 1I1fluence cell proliferation, the total cell num-
bcr, and th~refore the d.ata obtained with ELISA assays, changes in 
PN-E2 antIgen expressIon were assessed on a per-cell basis using a 
flo w cytometer. As ~ contr~l, the effects ofTNF-a on the expres-
sIOn ofICAM-l (FIg 1, rllld~le) and HLA-DR (Fig 1, right) were 
determllled. lCAM-1 expressIon was to a high degree upregulated 
by TNF, whereas HLA-DR expression levels were not altered. 
TNF-a treatment, however, downregulated the PN-E2 antigen 
expression by approximately a factor of 2. Dose-response studies 
showed that treatment of the cells with 10 nM TNF-a result . 
optimal. downregulation of the PN-E2 antigen (data not sho~I~~ 
Incubation of EC for vary1l1g penods of time with TNF-a showed 
tha~ downregulation was maximal after 30 h of treatment, after 
wlllch the PN-E2 antlgcn expression remained COnstant (data not 
shown). 
PN-E2 Antigen Is Expressed Weakly on Human Endothel' I 
Cells In Situ and Is Upregulated Under Pathologic C~=­
ditions A: large panel ofl1Uman tissues was screened to determine 
the exyressl?I1. levels ?f the P~-E2 antigen by using immunohisto-
chcmlcal staln ll1g o.f tissue sectIOns. Several components of the circu-
latory system, respiratory tract, urogenitalia, nervous system sk' 
d I d . I I . , In, a. n g an s Wit 1 extern a sccretiOn were assessed . From each g 0 
I II h I . . . r up, n.orma as we as pat 0 oglc tissues were 1I1vestigated. For each 
tissue, at least two samples were stamed. The staining patterns w 'th 
PN-E2 of a number. of representative tiss~es are shown in Fig 2\n 
general, the expression of t1:e PN-E2 antigen was restricted to Ee, 
With a weak, dlffusc expressloncfattcrn. Organ-related varl'ab'I ' ty . 
.. .. b' I I III 
s.ta1l1t1lg lI1tenSlty was 0 serve ; EC til heart muscle (P' 2) c 
I . d I kl Ig C, lor examp e, were stall1e on y wea y or not at all w hereas p r 't b I 
'11 . . k'd (F' 2 ) d ' e I u u ar capl anes III I ney Ig a an capillaries and larger ves I . I ' 
( . b) . se s 111 Iver 
. Fig 2 !lad more pronounced staming. In liver, a decreasin stain-
Ing gradient around the central vein was observed (Fig 2b) Ig 
. fib bl d h . n some tissues, ro asts an smoot muscle cells showed a we k . 
d . . d . 
a ' reaCtion, 
an In the kl ney, a marked mes?nglal staining was observed (Pi 
2a). Smaller vessels and capillanes often showed a I . g 
. . nore 111 tense 
stammg than larger vessels. All types of endothelium rd' I 
I PN E2 'b d . I d' eacte Wltl t l e - anti ~ y, mc u l.ng capillary, venous, arterial blood ves-
sel, and I Y I~lphatlc end~thebull1 (not shown). It is striking that the 
PN-E2 antigen expressIOn on EC was markedly increased' h 
I . I . . II . . 111 pat 0-oglc eSlOns, espeCla y 111 tissues with inflammato d' . 
T I
' . .. ry con ltlons. 
liS mcrease 111 expressIon was most pronoullced I'n k' . 
( . )! " . S 111 specimens Fig 3 . W lereas capIllaries 111 normal skin were '. 11 . d 
(F ' 3 ) '11 ' " fl mll1lma y stamc Ig a, capl anes 111111 amed skin (Fig 3b) were st ' d ' 1 
d . all1e ll1tense y Increase expression was also observed in skm' I' I . 
I· c . eSlOns w lere EC pro lIeraUon occurred, such as cutaneous mel (F' 3) d 
I . . (. anoma 19 c an granu anon tissue Fig 3d). Remarkably increa d . f I PN E2 . . ' se expression 0 t le 
- antigen was observed 111 a malignant endoth l ' 1 . (h 
. . e la tumor e-
manglOsarcoma) but not In a benign tumo (h . ) 
I d d · . r emangloma . 1n-vo ve an umnvolved skill biopsies of pat' t . I .. 
. d . h PN . len s Wit 1 psonaSls 
stal11e Wit -E2 and examllled by ilmnuno I . 
(F 4 d I) 1 e ectron mICroscopy 19 . a an 1 c eady showed the upregulation of the PN-E2 anti-
ge n 111 Illvo lved skill. The antigen was mainl d I I . I 'd f l ' y expresse on t le 
umll1a 51 e 0 t le endothelIUm. Higher magnifications (Fig 4c) 
showed that veSicles located directly below I I . I I 
b . t 1e Ul11ma p asma mcm rane werc stamed as wei\. Immul1ogold labeling of cultured 
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Figure 2. Staining pa~ternofPN-E2 in (a) huma~ kidney (magt~ification X 100), (b) liver (magnjfication X 100), (c) heart muscle (n?agnification X 200), and 
(d) lymph node (magmficatlon X.200), (frozen sections). No.testamlng of pentubular.cap!ilanes (arrowhead) and mesanglUm (armrll) In bdney (a). In liver (b), 
the central veins (arrow) were stamed mtensely, whereas stalllmg of surroundmg capillanes decreased m correspondence With distance to the central vein. EC 
(c) (arrow) in heart muscle were stained only weakly, whereas moderate stainjng was observed of lugh endotheltal vessels (d) (arrow) in lymph nodes. Bar, 
100 Jim (a, b) or 50 J1m (c, d) . Counterstained with hematoxylin. 
HUVEC confirmed that the antigen expression was restricted to the 
cell membrane (Fig 5). Additionally, PN-E2 antigen expression on 
leukocytes was assessed. Flow-cytometric analysis of monocytes and 
T cells isolated from peripheral blood incubated with PN-E2 
showed that monocytes expressed a low level of the PN-E2 antigen, 
whereas T lymphocytes were negative (Fig 6). In accordance with 
this observation, we found that the myeloid cell lines U937 and 
HL-60 were stained moderately an.d weakly, respectively, with 
PN-E2, whereas the lymphoid lines CEM, Daudi, and RPMI 8226 
and the erythromyeloid line K562 were negative (Fig 6). PN-E2 
expression on these cells was not affected by cytokine treatment 
(data not shown). 
PN-E2 Antigen Expression on Cultured Endothelial Cells is 
Only Modestly Affected by Inflammatory Cytokines To 
test whether the increased expression of the PN-E2 antigen in tis-
sues is mediated by inflammation.-associated cytokines, we analyzed 
the effect of treatment with various cytokines on the PN-E2 antigen 
expression on cu ltured ce lls. Consid~ring their constitutive high 
expression of the PN-E2 antlgen (Flg 1, left) , cultured HUVEC 
were not particularly suited for these studies. Therefore, we tested 
whether other cell types had a lower basal PN-E2 antigen expres-
sion. Figure 1 shows that the expression was high as well on cul-
tured HFEC (Fig 1, middle) but moderate on fibroblasts (Fig 1, right). 
We incubated HUVEC, HFEC, and fibroblasts with various con-
centrations of IL-1O', IL-IP, IL-4, IL-6, IFN-y, TNF-O', LPS, or 
bFGF. None of the tested. cytokines had PN-E2 upregulating effects 
as dramatic as observed 111 II1flammatory lesions. Incubation with 
IL-1O', IL-IP, IL-4, IL-6, LPS, or bFGF had no effect at all. As can be 
seen in Fig 1 (left), '!'NF-O' lowered the expression by a factor of2 011 
HUVEC, whereas It had no effect on the PN-E2 expression level on 
HFEC and fibroblasts. IFN-y caused a twofold increase in PN-E2 
antigen expression on both HUVEC and HFEC, but no effect waS 
observed on fibroblasts. V~rying incl1ba~ion times with the cyto-
kll1es between 4 and 72 h did not alter their effect. Control stainings 
showed that in all three tested cell types, both IFN-y and TNF-l! 
increased the ICAM-l expression, whereas HLA class II molecules 
we.re only upregulated by IFN-y. Remarkably, however, a subpopu-
latlO11 of HFEC (- 20% of the cells) showed extensive HLA class II 
upregulation after TNF-O' treatment. 
Mol~cular Weight of the PN-E2 Antigen To determine the 
relative molecular 'mass of the PN-E2 antigen lysates of 
[35S]methionine- labeled unstimulated and TNF-O'- treated 
HUVEC were immunoprecil?itated with PN-EB, CL203 (both 
ICAM-I), W6/32 (major lustocompatibili ty complex class I), 
WT32 (CD3), and PN-E2 and analyzed on SDS-I0% PAGE 
under reducing condit~ons (Fig 7). Both PN-E8 and CL203rrecipi-
tated bands of approxImately 100 kDa from the Iysates 0 stimu-
lated cells. W6j32 ~et.ected a ba~d of 45 kDa from both Iysates, 
whereas PN-E2 preClpltated a major band of 90 kDa and a minor 
band of 80 kDa from lysates of both stimulated and unstimulated 
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·Figure 3. Staining pattern ofPN-E2 in (a) healthy human.skin (magnification X200) ~ (b) 110n-spccificd enn atitis specimen taken from skin in the coxa area 
(magnification X 100), (e) cutaneous melanoma (magl1lficatlon X 200), and (d) granulatIon tIssue (l11agruficatlOn X 100). Note II1creased expression ofPN -E2 
antigen on EC (Ii -d) compared with normal tissue (a) (arrolll). Bar, 100 11m (b , d) or 50 11m (a, c). Countersta llled wIth hematoxylin. 
cells. Control monoclonal antibody WT32 (anti-CD3) did not de-
tect any specific bands. Under non-reducing conditions, PN-E2 
precipitated bands of180 and 400 kDa. T he ~N-E2 antigen may ~e 
a homodimer consist1l1g of two 90-kDa cha1l1s (the 80-kDa cha1l1 
being a degradation product of the 90-kDa chain), or, alternatively, 
a heterodimer consisting of a 90- and a 80-kDa chain, the latter 
chain being less intensely labeled. Attempts to detect the PN-E2 
antigen by immunoblotting techniques were unsuccessful. 
DISCUSSION 
In this study, we describe a new antigen, recognized by the PN-E2 
monoclonal antibody, of which the expression ill situ is largely 
restricted to Ee. Organ-specific variability in the intensity of the 
PN-E2 antigen expression on endothelium was observed. In most 
tissues, the expression level on EC ran ged from weak to moderate, 
but the endothelium of the peritubular capil laries in the kidney was 
stained intensely. All types of endothelium were stained, with a 
tendency of decreasing expression in vessels of increasing size. Im-
munoelectron microscopy studies revealed that the molecule was 
predominantly expressed on the luminal membrane of the EC. 
Small, subluminal vesicles were stained as well , indicating that the 
PN-E2 molecule is internalized by endocytosis. This staining may 
reflect a specific and passive uptake of the molecule, but a possible 
role of the molecule in endocytosis is not excluded. Remarkably, the 
PN-E2 antigen expression was considerably increased in tissues 
where the endothelium could be assumed to be activated or was in a 
state of active proliferation. This increase in expression was most 
pronounced in the skin, as demonstrated by the staining of inflamed 
skin, skin of a patient with psoriasis, cutaneous melanoma, and 
granulation tissue. The increased PN-E2 antigen expression under 
inflamm.atory circums~ances su.ggested that inflammatory media-
tors could modulate this expressIOn. We could not, however, mimic 
this upregulation ill vitro. Stimulating HUVEC, HFEC, or fibro-
blasts with a large panel of cytokines and other biologic response 
modifiers (IL-la, IL-fl., IL-4 , IL-6, IFN-y, bFGF, LPS, TNF-a) did 
not have the dramatic eJ!ect observ~d in situ. TNF-a slightly 
downregulated PN-E2 antigen expreSSIon, whereas IFN-y induced 
an upregulation of approximately a factor of 2. The other tested 
mediators had no effect at all. Our failure to induce upregulation of 
the PN-E2 an~igen i" vitro n:ay be du~ to. the fact that the cell types 
",!e t~s ted prevlo;lsly had. a hIgh constitutive PN-E2 antigen expres-
sIon 111 the absence of stimulatory treatment. This high expression 
may have been an effect of the. culture conditions (e.g., factors 
present 111 the h~man s~rum ~sed In the culture medium). Culturing 
the cel ls for 3 d 111 medIUm WIthout human serum, however, did not 
alter the PN-E2 antigen express i<:>n (data not shown). Alternatively, 
the fact that cells prohferated III culture may have induced the 
upregul~t ion~ because in tissues w here angiogenesis occurred (e.g., 
granulation tissue), the endothelium also strongly reacted w ith the 
PN -E2 monoclonal antibody. Finall y, the effect of other inflamma-
tory cytokines on PN-E2 antigen expression will have to be tested 
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Figure S. Ultracryosections showing immunogold labeling of cu ltured 
HUVEC by PN-E2 (magnification X 30,000; gold particles 10 nm). Note 
that labeling is restricted to the cell membrane (arrolll). C, cytoplasm; N, 
nucleus. 
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Figure 4. Staining by PN-E2 of a capillary in (0) uninvolved (magnificatiOn 
X 10,000) and (b) involved (magnification X 10,000) skin of a patient with 
psoriasis as assessed. by preembedding, immunoelectron microscopy. (c) 
Note IIlcreased staInlllg wIth PN-E2 Inlllvolved skin and staining of sub-
membrane vesicles (magnification X 30,000). E, endothelial cel l; L, lumen. 
Bar, 1 11m (a,b) or 0.33 11m (c). Contrasted with uranyl acetate. 
... CELL NUMBER 
Monocyles U937 HL60 
~ LOG FLUORESCENCE INTENSITY 
Figure 6. Flow cytometric a~al ysis of PN-E2 binding to purified mono-
cytes, T cell s, and varIOUS cellllllcs: .. . controls (buffer instead of mono-
clonal antibody); -stained with PN -E2 . . 
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Figure 7. Immunoprecipitation of l;'roteins by antibodies PN-E2, PN-E8 
(reAM-1), CL203 (ICAM-1), W6/32 (HLA class I), and WT32 (CD3; 
negative control) from [35S]methionine- labeled cell lysates of untreated 
HVVEC (left) or HUVEC treated with 10 nM TNF for 3 d (right). SDS-
PAGE analysis was performed under reducing conditions. Molecular 
weights of marker proteins are shown on the "ertical axes. OD, optical 
density. 
(e .g., IL-8 has recently been described to have inflammatory proper-
ties in skin [14]) . 
A number of molecules have been described that are upregulated 
on dermal EC under inflammatory conditions and in various patho-
logic lesions. These include molecules involved in adhesion of leu-
kocytes to EC, such asE-selectin, VCAM-1, and ICAM-1, and HLA 
class II molecules (15 -17). A comparison, however, of these inflam-
matory EC-associated molecules with the PN-E2 antigen reveals 
characteristics incompatible with respect to molecular weight, tis-
sue distribution, and expression kinetics under influence of cyto-
kines in vitro or in inflammatory lesions in Vil/O. E-selectin is in vitro 
upregulated by TNF-a and IL-l, with peaking expression levels at 
4 - 6 h and loss of expression at 24 h [7,8] . PN-E2 antigen expres-
sion, on the other hand, is constitutively high on unstimulated 
endothelium and is slightly downregulated by TNF-a. VCAM-l is, 
in contrast to the PN-E2 antigen, not present on resting EC in vitro 
[5,6,18]. Both ICAM-l and HLA class II molecules have a low level 
of expression on HUVEC and are upregulated by TNF-a and IFN-y 
and by IFN-y, respectively [8,19-23}. 
The PN-E2 antigen has a number of characteristics in common 
with the previously described endoglin molecule (formerly called 
44G4 antigen) [24,25]. The molecular weight of endoglin (95 kDa 
under reducing and 170 kDa under non-reducing conditions) is 
similar to the molecular weight of the PN-E2 antigen (90 kDa 
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reduced and 180 kDa non-reduced). The 80- and 400-kDa immun-
oprecipitates we observed for the PN-E2 antigen under reducing 
and non-reducing conditions, respectively, however, were not de-
scribed for endoglin. Tissue distribution patterns of endoglin and 
PN-E2 also show remarkable similarities. Both molecules are irl situ 
predominantly expressed on EC, whereas endoglin expression on 
cultured macrophages and phorbol myristate acetate (PMA)-
treated U937 and HL-60 cells was recently described [26]. Endog-
lin, however, was absent from peripheral blood monocytes [26,27], 
whereas the PN-E2 antigen has a low but distinct expression level 
on these cells. Also, PN-E2 expression on unstimulated U937 and 
HL-60 cells appears to be higher than endoglin expression (26). We 
are planning to assess PN-E2 expression on cultured macrophages 
a.nd .on PMA-tre~t~d l!937 a~ld HL-60 cells. Furthermore, sequen-
nallmmunopreClpltatlons With PN-E2 and an antiendoglin mono-
clonal antibody will have to be performed to prove whether endog-
lin and the PN-E2 antigen are identical. 
~on?c1onal antibody PN-:'32 m~y b.e a useful tool in visualizing 
EC I~ tls.sues where endotheltal activation occurs, especially in skin. 
ElUCidation of the z:ature of the PN-E2 antigen may teach us more 
about the. ~haractenstlcs ofEC under activating or growth-promot-
mg condltlons. 
Note Added in Proof Specific binding of the PN-E2 monoclonal 
antibody to two independently derived sets of mouse L-cell endo-
gl~n transfectants w~s obs~rved by flo~ cytometry, confirming that 
thiS monoclonal antlbod~ IS r~act1ve ~Ith ?uman endoglin (c. Ber-
nabeu, Centro de InvestigaclOnes BlOloglcas, Madrid and M. Le-
tarte, Hospital for Sick Children, Toronto). 
We tlrallk I. Otle-Holler alld M. Me1gers-Arends Jor pe.Jormillg tire immunoelectrOtI 
microscopy studies; Dr. E. Rulo, Departmellt oJDermatology, Ulliversity Hospital 
Nijmegell, Jor prollidillg skill biopsies oj psoriatic patiellts; C. Jacobs alld W. Tam-
boer, DeparlmetJI of Nephrology, Ulliversity Hospital Nijtllegen,Jor performillg the 
Jluorescetlce-actillated cell sorler allalyses; alld Dr. A . Duits, Department oj Experi-
metltallmllllltlOlogy, Uuillersity Hospital UtrechtJor testing thePN-E antibodies OIl 
ICAM-1-trausJected COS cells 
JRW ,vas supported by a grant Jrom the Nijmegen University Research Pool. 
REFERENCES 
1. Ruiter DJ, Schlingemann RO, Rietveld FJR, De Waal RMW: Mono-
clonal antibody defined human endothelial antigens as vascular 
markers. J Invest Dermatol 93:25S - 32S, 1989 
2. Schlingemann RO, Dingjan .GM, Emeis J] , Blok J. Warnaar SO, 
RUiter DJ: Monoclonal antibody PAL-E specific for endothelium. 
Lab Invest 52:71-76. 1985 
3. Pober JS: Cytokine-mediated activation of vascular endothelium. Am 
J PathoI133:426-433, 1988 
4. Pober JS, Cotran RS: Cytokines and endothelial cell biology. Physio! 
Rev 70:427-451,1990 
5. Graber N, Gopal TV, Wilson D. Beall LD, Polte T. Newman W: T 
cells bind to cyrokine-activated endothelial cells via a novel induci-
ble sialoglycoprotein and endothelial leukocyte adhesion m'olecule-
1.J Immunol145:819-830. 1990 
6. Osborn L, Hession e. Tizar.d R, Vassallo C, Luhowskyj S, Chi-Rosso 
G, Lobb R: Direct expreSSIon cloning of vascular cell adhesion mole-
cule 1, a cytokme-mduced endothelial protein that binds to lympho-
cytes. Cell 59:1203-1211, 1989 
7. Leeuwenber~JFM.Jeunhomme TMAA, Buurman WA: Induction of 
an activatIOn antlgen on human endothelial cells in vitro. Eur J 
Immunol 19:715-720, 1989 
8. PoberJS, Bevilacqua M~, ~endrick DL, Lapierre LA, Fiers W, Gim-
bronc MA Jr: Two dlstmct monoklnes, interleukin 1 and tumor 
necrosis factor, each independently induce biosynthesis and tran-
sIent expressIOn of the same antigen on the surface of culrured 
human vascular endothelial cells. J Immuno1136:1680 -1687,1986 
9. Poher JS, <;ocran RS: What can be learned from the expression of 
endotheltal adheSIon molecules in tissues? Lab Invest 64:301-305 
1991 ' 
34 WESTPHAL ET AL 
10. Jaffe EA, Nachman ER, Becker CE, Minick C: Culture of human 
endothelial cells derived from human umbilical veins. J Clin Invest 
52:2745 - 2756,1973 
11. Maciag T, Cerundolo J, Ilsly S, Kelley PR, Forrand R: An endothelial 
cell growth factor from bovine hypothalamus: identification and 
partial characterization. Proc Nat! Acad Sci USA 76:5674-5678, 
1979 
12. Maio M, Tessitori G, Pinto A, Tempori M, Colombatti A, Ferrone S: 
Differential role of distinct determinants of intercellular adhesion 
molecule-1 in immunologic phenomena. J Immunol143: 181-188, 
1989 
13. Tamura GS, Dailey MO, Gallatin WM, McGrath MS, Weissman IL, 
Pillemer EA: Isolation of molecules recognized by monoclonal anti-
bodies and antisera: the solid phase immunoisolation technique. 
Anal Biochem 136:458-464, 1984 
14. Swensson 0, Schubert C, Christophers E, Schroder J-M: Inflamma-
tory properties of neutrophil-activating protein-1/interleukin 8 
(NAP-1/IL-8) in human skin: a light- and electronmicroscopic 
study. J Invest DermatoI96:682-689, 1991 
15. Norris P, Poston RN, Thomas DS, Thornhill M, Hawk J, Hashrd 
DO: The expression of endothelial leukocyte adhesion molecule-1 
(ELAM-1), intercellular adhesion molecule-1 (ICAM-1), and vascu-
lar cell adhesion molecule-1 (VCAM-1) in experimental cutaneous 
inflammation: a comparison of ultraviolet B erythema and delayed 
hypersensitivity. J Invest Dermatol 97:190-196, 1991 
16. Swerlick RA, Garcia-Gonzalez E, Kubota Y, Xu Y, Lawley T): Studies 
on the modulation of MHC antigen and cell adhesion molecule 
expression on human dermal microvascular endothelial cells. J In-
vest DermatoI97:190-196, 1991 
17. Nickoloff BJ, Griffiths CEM: Aberrant intercellular adhesion mole-
cule-I (ICAM-1) expression by hair-follicle epithelial cells and en-
dothelialleukocyte adhesion molecule-1 (ELAM-1) by vascular cells 
are important adhesion-molecule alterations in alopecia areata. J 
Invest Dermatol 96:91S-92S, 1991 
18. Carlos TM, Schwartz BR, Kovach NL, Vee E, Rosso M, OSbOCll L, 
Chi-Rosso G, Newman B, Lobb R, Harlan JM: Vascular cell adhe-
sion molecule-l mediates lymphocyte adherence to cytokine-acti-
·vated cultured human endothelial cells. Blood 76:965-970,1990 
THE JOURNAL OF INVESTIGATIVE DERMATOLOGY 
19. Dustin ML, Rothlein R, Bhan AK, Dinarello CA, Springer T A: Induc-
tion by IL- l and interferon-gamma: tissue distribution, biochemis-
try, and function of a natural adherence molecule (ICAM-l). J Im-
munol 137:245-254, 1986 
20. Pober JS, Gimbrone MA Jr, Lapierre LA, Mendrick DL, Fiers W, 
Rothlein R, Springer T A: Overlapping patteClls of activation of 
human endothelial cells by interleukin-1, tumor necrosis factor, and 
immune interferon. J Immunol 137:1893 - 1896, 1986 
21. Pober JS, Lapierre LA, Stolpen AH, Brock TA, Springer TA, Fiers W, 
Bevilacqua MP, Mendrick DL, Gimbrone MA Jr: Activation of 
cultured human endothelial cells by recombinant Iymphotoxin: 
comparison with tumor necrosis factor and interleukin 1 species. J 
Immunol138:3319-3324,1987 
22. Pober JS, Gimbrone MA Jr, Cotran RS, Reiss CS, Burakoff SJ, FiefS 
W, Ault KA: la expression by vascular endothelium is inducible by 
activated T cells and by human gamma interferon. J Exp Med 
157:1339-1353,1983 
23. Leeuwenberg JFM, Van Damme J, Meager T, Jeunhomme TMAA, 
Buurman W A: Effects of tumor necrosis factor on the interferon-
gamma-induced major histocompatibility complex class II antigen 
expression by human endothelial cells. Eur J Immunol 18:1469-
1472, 1988 
24. Gougos A, Letarte M: Biochemical characterization of the 44G4 anti-
gen from the HOON pre-B leukemic cell line. J Immunol 
141:1934-1940,1988 
25. Gou.gos A, Letarte M.: Primary structure of endoglin, :111 RGD-con- , 
tammg glycoprotem of human endothelial cells. J Bioi Chem 
265:8361-8364, 1990 
26. Lastres P, Bellon T, Cabanas C, Sanchez-Madrid F, Acevedo A, 
Gougos A, Letarte M, Bernabeu C: Regulated expression on human 
macrophages of endoghn, an Arg-Gly-Asp-containing surface anti-
gen. Eur J ImmunoI22:393-397, 1992 
27. Gougos A, Letarte M: Identification of a human endothelial cell anti-
gen with monoclonal antibody 44G4 produced against a prc-B leu-
kemic cell line. J ImmunoI141:1925-1933, 1988 
